Medincell

Advancing the next generation of Long‑Acting Injectables: Medincell will attend PBP World Meeting 2026 with Adolfo López-Noriega, Christophe Roberge & Anthony Rech. See visual for our talk & session times. #PBP2026 #Biopharmaceutics #LongActingInjectables #DrugDelivery

Medincell will be at #BIOEuropeSpring! James Gubbins, PhD, will be in Lisbon (Mar 23–25) to explore partnerships and present our BEPO® LAI technology. 🤝Want to meet? Contact James via the partnering platform. #BIO #BIOEurope #Biotech #Pharma #Partnering #BIOEuropeSpring2026

@MedinCell has raised €48M to advance key programs, boost our LAI platform, and strengthen future partnerships. Thank you to all supporting investors. 🔗 More details: medincell.com/successful-c-e…

📢 MedinCell HY Results Videoconference 🗓️ Dec 10, 2024 🇫🇷 6 PM CET (French): medincell.com/fr/live-fr 🇬🇧 7 PM CET (English): medincell.com/live-en Join us to hear our latest updates. #MedinCell #HYResults #CorporateEvent

Participez à notre Webinaire Recherche & Développement le jeudi 10 octobre à 18h00 Pour vous connecter : lnkd.in/eGdKnbAr Vous pouvez envoyer vos questions d'ordre scientifique et médical à communication@medincell.com, [Réunion en français]

📻 This morning, @christophedouat Douat was featured on @radioclassique , interviewed by @FrancoisGeff. It was a great opportunity to highlight the recent successes of Medincell and share what's coming next. 📢 Tune in to listen to the full interview here: smartlink.ausha.co/la-france-de-d…

@christophedouat Douat, CEO, and Richard Malamut, CMO, to present Medincell's portfolio and R&D pipeline at the Jefferies Global Healthcare Conference To access the presentation remotely, either live or on replay: wsw.com/webcast/jeff30… #JefferiesHealthcare

🌐✨ We are thrilled to unveil Medincell's new corporate website, designed to offer a more user-friendly, informative, and visually stunning online experience. This reflects our unwavering dedication to healthcare innovation. As Medincell embarks on a new era, this launch represents more than just a new website. It signifies a leap forward in how we connect, communicate, and collaborate, aiming to positively impact Global Health 🌍🌎🌏. Visit medincell.com #Medincell #HealthcareInnovation #GlobalHealth

Jefferies Initiates MedinCell’s Coverage with a “Buy” Recommendation Jefferies, one of the world’s leading international full-service investment banking and capital markets firms has initiated coverage of Medincell.  Jefferies analysts initiated coverage with a "Buy" rating and price target of €12, marking a +74% potential increase from yesterday market close. They wrote: “We view Medincell as the best positioned long acting injectables players, underpinned by best-in-class drug delivery technology, which should see it outperform competitors in growing blockbuster indications.” Read the press release: lnkd.in/eWGTmg-m

Follow our half-year earnings call, today at 6:30pm CET > To watch the meeting in French: #events_" target="_blank" rel="nofollow noopener">medincell.com/fr/investisseu… > To watch the meeting in English: #events_" target="_blank" rel="nofollow noopener">medincell.com/en/investors/#…

🚀 MedinCell applauds @TevaUSA and @RoyaltyPharma collaboration to further accelerate olanzapine LAI program (mdc-TJK), an innovative approach to schizophrenia treatment. 💡 Investment in Innovation Teva has secured an investment of up to $125M from Royalty Pharma to advance mdc-TJK, a therapy with the potential to be the first of its kind for schizophrenia. Ongoing Phase 3 trial results are now expected earlier than anticipated in the second half of 2024. 🤝 Confidence in Progress The renowned expertise and robust track record of Royalty Pharma lend substantial confidence to the value and transformative potential of mdc-TJK. 🔍 Commitment to Care Great to witness Teva's commitment to accelerating the development of this promising therapy, which could significantly impact the lives of patients with schizophrenia. For more information on this promising development: Teva’s Press Release: lnkd.in/e4XBCBxS MedinCell’s Press Release: lnkd.in/eSkUMwCu #MedinCell #TevaPharmaceuticals #RoyaltyPharma #MentalHealthInnovation #SchizophreniaCare

📌 Save the Date! Join MedinCell's CEO Christophe Douat & CMO Richard Malamut at the Jefferies London Healthcare Conference. 🗓️ Nov 16, 1:30pm GMT 🔗 Tune in live or watch the replay: wsw.com/webcast/jeff28… Excited to showcase our latest in #HealthcareInnovation. Stay tuned! #JefferiesConference

🔬 Exciting News! This week, The @TheLancetPsych publishes the results from the Phase 3 RISE study of UZEDY, championed by our partner @TevaUSA Pharmaceuticals. Study findings played a pivotal role in securing FDA approval for UZEDY in April 2023, marking a new step in treating schizophrenia in adults through a convenient subcutaneous injection every 1-2 months. 🌟 What makes UZEDY stand out? It's the pioneering product harnessing the power of MedinCell BEPO technology, licensed to TEVA as SteadyTeq, bringing innovative treatment options to our patients. 📖 Dive into the detailed RISE study findings: lnkd.in/eE_iB2tr

RT @LePointEvents: J-1 ! 📣 Tenez-vous prêts… pour #FuturapolisSanté 2023 ! Sortez vos cahiers et stylos ! 📝 #Conférences captivantes, #at…

MedinCell and the European Investment Bank (@EIB) have replaced a financial covenant of their ongoing loan agreement to better fit with MedinCell business model Christophe Douat, CEO of MedinCell said: “The European Investment Bank is a strategic partner for many years with in-depth knowledge of MedinCell EIB knows that MedinCell has a good financial health and a tremendous prospects following the successful launch of Uzedy and thanks to the progress of our portfolio of breakthrough medicines. As partners with aligned interests, we have decided to evolve our agreement by considering the specific requirements of each party.” Read the full PR: medincell.com/en/2023/10/04/…

Welcome aboard Grace Kim! US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell #BetterMedicineForAll #ImpactHealth #IR Full PR: medincell.com/en/2023/09/06/…

MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement Full story: medincell.com/en/2023/08/30/… #BetterMedicineForAll #ImpactHealth #TKR

Our Annual General Meeting and Extraordinary General Meeting will be held at MedinCell’s headquarters on Tuesday, September 12, 2023, at 6.00 p.m. CEST. Prior to it, we will hold a video conference on Tuesday, September 5, 2023, at 6 p.m. to present the resolutions of & answer questions from shareholders.  Connection link: lnkd.in/dmuxKmXu All details in English: lnkd.in/dJK2qwbi Toutes les modalités en français : lnkd.in/daP4Tgp4

MedinCell’s partner @TevaUSA announces successful launch of UZEDY™ Full PR: medincell.com/en/2023/08/02/… #BetterMedicineForAll #ImpactHealth #Tevapharm